Skin Cancer Connect Newsletter | Castle Biosciences

Expert consensus panel report recommends DecisionDx-SCC

The panel's unanimous adoption of consensus statements and recommendations of Castle Biosciences' DecisionDx-SCC prognostic test is the focal point of the article. A distinguished panel of eight dermatologists with specialized expertise in the diagnosis and management of squamous cell carcinoma, convened to analyze 21 pertinent articles on the utilization of gene expression profiling (GEP) testing for assessing risk of metastasis in cSCC.

Learn more

Featured content

Head-to-head study in Stage I patients demonstrates that DecisionDx-Melanoma outperforms AJCC8

In a head-to-head comparison of DecisionDx-Melanoma to AJCCv8 staging for stage I cutaneous melanoma (CM) patients (n=6,882) two cohorts were analyzed using recurrence-free survival and melanoma-specific survival. Results from the study showed that DecisionDx-Melanoma significantly improved patient risk stratification, independent of AJCC staging in patients. In addition, DecisionDx-Melanoma provided greater separation between high-risk (Class 2B) and low risk (Class 1A) groups than seen between AJCC stage IA and IB.

Read more
New DecisionDx-SCC study shows significant Medicare savings when test is used to inform Adjuvant Radiation Therapy decisions

A new publication titled “Use of the 40-gene Expression Profile (40-GEP) Test in Medicare-eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs” finds that using DecisionDx-SCC to guide patient selection for ART, identifying patients with cutaneous squamous cell carcinoma (SCC) who can safely forgo the treatment with upwards of a $900 million net cost savings to Medicare.

View publication
On-Demand: Resolving diagnostic ambiguity with gene expression profile testing in challenging melanocytic lesions

In this edition of our "Cases with Castle Biosciences" series, Clay Cockerell, MD, Founder and President of Cockerell Dermatopathology, discusses real-world cases where diagnostic GEP testing was incorporated into the diagnostic workup of difficult-to-diagnose melanocytic lesions.

View webinar